RxDoctor Payments Data

Nathan Spencer

Physical Medicine & Rehabilitation · Richland, WANPI 1376038109

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,614 of the $2,263 with a category attached, or 71.3%. Pacira Pharmaceuticals Incorporated accounts for 77.4% of it on its own, with 7 other manufacturers making up the rest. 2024 is the largest year on record at $1,755, more than ten times the $12 reported in 2020.

$2,263in general payments, 2019–2025

Across 20 payments — averaging $113.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$2K
  • Ipsen Biopharmaceuticals, Inc$238
  • Averitas Pharma Inc.$77
  • Collegium Pharmaceutical, Inc.$54
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$54
  • GRT US Holding, Inc.$45
  • plus $42 from 2 others

What the payments were for

  • Travel & lodging$1,61471%
  • Food & beverage$65029%

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,263 in reported general payments places this provider in the 85th percentile of 260 physical medicine & rehabilitation providers in Washington.

See all physical medicine & rehabilitation providers in Washington

Medicare billing

Part B allowed, 2024
$130,165
Medicare patients
486
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate12$16,986
BelbucaBuprenorphine Hcl12$9,256
Pregabalin236$4,879
Xtampza ErOxycodone Myristate14$2,631
Baclofen130$2,417
Duloxetine Hcl143$2,067
OxycontinOxycodone Hcl11$1,728
Gabapentin87$1,341
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$633
Oxycodone Hcl54$589
Diclofenac Sodium27$509
Tizanidine Hcl13$401
Celecoxib12$345
Meloxicam63$323
Nortriptyline Hcl16$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$54$11,88726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 260 physical medicine & rehabilitation providers in Washington.

Other physical medicine & rehabilitation in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →